J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 10, Number 3, March 2018, pages 178-181

Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)

Figure

Figure 1. Kaplan-Meier curves for overall survival: molGPA 4.0 (3.5 - 4 points, n = 6) vs. molGPA 3.0 (2.5 - 3 points, n = 7) vs. molGPA 2.0 (1.5 - 2 points, n = 23) and molGPA 1.0 (0 - 1 points, n = 33), P = 0.0001 (pooled over all strata).

Tables

**Table 1.** Calculation of the Prognostic Score, as Reported by Sperduto et al [12]
Parameter	0 points	0.5 points	1 point
Age ≥ 70 years	x
Age < 70 years		x
KPS ≤ 70	x
KPS 80		x
KPS 90 - 100			x
Presence of extracranial metastases	x
Absence of extracranial metastases			x
More than four brain metastases	x
2 - 4 brain metastases		x
1 brain metastasis			x
Negative/unknown BRAF status	x
Positive BRAF status		x

**Table 2.** Pretreatment Characteristics of All 69 Patients Included in This Study
Parameter	Number	Percent	Median overall survival in months	P-value (log-rank test)
KPS: Karnofsky performance status; WBRT: whole-brain radiotherapy.
Female gender	30	43	5.9
Male gender	39	57	4.8	0.38
Extracranial metastases absent	12	17	12.1
Extracranial metastases present	57	83	3.7	0.003
KPS ≤ 70	25	36	2.0
KPS 80	18	26	5.8
KPS 90 - 100	26	38	11.8	0.0001
Single brain metastasis	11	16	12.1
2 - 4 brain metastases	25	36	7.9
> 4 brain metastases	33	48	2.3	0.0001
Age < 70 years	50	72	7.3
Age ≥ 70 years	19	28	2.7	0.001
BRAF positive	9	-	7.3
BRAF negative	12	-	2.1	0.08
WBRT	48	70	3.1
Surgery/stereotactic RT	21	30	12.1	0.0001

**Table 3.** Comparison of the Median Survival Results in Months With Those Reported by Sperduto et al [11, 12]
Study	n	All patients	DS-GPA unfavorable	DS-GPA intermediate	DS-GPA second best	DS-GPA best
DS-GPA: diagnosis-specific graded prognostic assessment score (in this case limited to patients with malignant melanoma).
Sperduto et al [11]	483	6.7	3.4	4.7	8.8	13.2
Nieder et al [3]	51	3.7	3.1	3.7	7.5	12.7
Sperduto et al [12]	823	9.8	4.9	8.3	15.8	34.1
Present study	69	5.4	2.1	7.8	11.8	18.0